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Chronic hepatitis C virus (HCV) infection frequently 
leads to liver cirrhosis (1), which is a major risk factor for 
hepatocellular carcinoma (HCC) and liver failure. Together, 
these two complications account for nearly half a million 
HCV-related deaths every year, world-wide (2). In contrast 
to other blood borne viruses such as HIV and hepatitis 
B, chronic HCV is a curable infection. Yet until recently, 
few HCV cirrhosis patients were able to achieve a cure 
because standard-of-care therapies were ineffective (<30% 
chance of cure) and entailed significant adverse effects (3). 
The arrival of direct acting antiviral (DAA) therapies has 
turned this situation full-circle. By directly interfering 
with the HCV lifecycle, DAA regimens cure more than 
95% of cirrhosis patients in 8–12 weeks (4). Adverse effects 
are minimal. Thus, since the availability of DAAs from 
circa 2014–2015, the number of cirrhosis patients who 
have achieved a cure has increased dramatically. But an 
HCV cure is not a panacea; patients with cirrhosis who 
achieve a cure still remain at increased risk of developing 
HCC (5). Consequently, clinical guidelines recommend 
that all patients should continue to receive bi-annual 
ultrasound screening indefinitely after a cure. Screening 
can detect HCC at an incipient stage when prognosis is 
most favourable, but conversely, it is can also cause harm 
vis-a-vis false positive findings and unnecessary follow-up 
investigations (6). Thus, there is a growing appetite among 
clinicians to move towards a more individualised approach 
to HCC, i.e., targeting those who stand to gain the most 
from screening as opposed to patients who stand to benefit 
minimally or not at all. But to achieve this, robust risk 
stratification tools are needed. 
It is against this backdrop therefore, that Pons et al., in a 
recent Journal of Hepatology study, have created a new HCC 
risk profile tool for cured HCV patients (7). Their tool takes 
information about a patient’s liver stiffness measurement 
(LSM) 1 year after completing treatment + their pre-
treatment albumin level, and then converts that information 
into a 1-, 2- and 3-year predicted risk of HCC. It was created 
from analysing HCC incidence data in a cohort of 572 
patients with “advanced compensated chronic liver disease” 
who have achieved an HCV cure. Advanced compensated 
chronic liver disease—which can be considered as broadly 
equivalent to compensated liver cirrhosis (8)—was defined 
on the basis of a pre-treatment fibroscan score ≥10 kPa with 
no prior history of decompensation (ascites, bleeding varices, 
encephalopathy or jaundice). All patients were treated at 1 
of 2 hospitals in Barcelona, and were followed-up for 2.8 
years on average post-cure. During this follow-up period, 
25 patients developed HCC, equating to an incidence rate: 
1.5 events per 100 person years. Using regression analysis, 
the authors assessed a total of 27 candidate predictors 
for association with HCC incidence. Only two of these 
predictors were significantly associated in multivariate 
analysis at P<0.05. These were: (I) baseline albumin, and (II) 
liver stiffness 1 year after starting therapy. On the basis of 
these two variables, the authors divided patients into four risk 
groups, and observed distinct HCC risk profiles in each, i.e., 
from a HCC incidence rate of 0.9 per 100 person years (for 
patients with albumin >4.4; and LSM <10 kPa) to a HCC 
incidence rate of 3.7 per 100 person years (for patients with 
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albumin <4.4 g/dL, and LSM >10 kPa). 
Previous studies report that most patients exhibit 
a rapid improvement in routine liver blood tests [e.g., 
platelet counts, alanine aminotransferase (ALT), aspartate 
aminotransferase (AST), fibrosis-4 (FIB-4); AST to Platelet 
Ratio Index (APRI)] and LSM immediately after achieving 
a cure (9). But some patients do not, and some patients 
worsen. It is intuitive to surmise that, ceteris paribus, a 
patient who exhibits improvement in LSM/platelet counts/
ALT levels, may have a better prognosis versus a patient 
who does not. But history tells us that what is intuitive and 
what is correct are not always one and the same! Thus, a 
key strength of Pons et al.’s study is that, to an extent, they 
were able to empirically test this hypothesis. Specifically, 
they assessed whether a patient’s change in liver stiffness 
between starting treatment and achieving a cure, is useful 
as a prognostic factor for subsequent HCC risk. Amongst 
patients in their cohort, the mean LSM was 20.2 kPa at 
the start treatment and 13.9 kPa 1 year after completing 
therapy. Overall, 57% of the HCC cases exhibited >20% 
improvement in LSM versus 71% of the controls/non-
cases. But in univariate Cox regression analysis, LSM 
improvement was not significantly associated with 
subsequent HCC incidence (P=0.131), and on this basis, the 
authors did not consider it further. So, does this mean that 
change in prognostic factors such as LSM and liver blood 
tests should not be explored further? No. Because of their 
small sample size, the non-significant result observed could 
reflect a type 2 error as opposed to a true null effect (see 
later discussion on statistical limitations). Interestingly, two 
very large overlapping studies based on cured HCV patients 
from the US Veterans cohort have just been published; 
both indicate that improvement in FIB-4/APRI score, is a 
very strong predictor of HCC risk following an HCV cure 
(10,11) More research in this territory is needed. 
Another strength of Pons et al.’s study is that they provide 
data on the rate of incident decompensation among cured 
patients with advanced compensated chronic liver disease—
something for which there has been scant data thus far. On 
this front, the authors indicate that five patients developed 
decompensation during follow-up (defined as ascites, 
encephalopathy, bleeding varices, or jaundice), equating 
to an event rate of 0.34 events per 100 person years. This 
suggests that incidence rate of de novo decompensation is 
relatively low following cure, and much less frequent than 
incident HCC. But more data on this front are needed. 
The Pons et al. study has limitations as well as strengths. 
Firstly, their sample size of 572 is small insofar as only 30 
patients developed an outcome of interest (25 with HCC 
and 5 with decompensation). As a rule, prognostic models 
developed from small sample sizes do not perform as well 
when tested on independent datasets. The low number 
of events is likely to have hampered the identification of 
bona fide predictors of HCC development. For example, 
in univariate analysis, the authors initially considered 27 
prognostic factors for association with HCC incidence, 
and selected only four that were significant at P<0.1 for 
consideration in multivariate analysis. But it is possible, 
that some or many of the 23 prognostic factors that were 
not selected for multivariate analysis, may nevertheless 
be important, but were not identified only because of 
inadequate statistical power, as opposed to a true lack of 
predictive value (i.e., type 2 error). Also, whilst assessing the 
predictive power of LSM 1 year after completing therapy (as 
opposed to prior to treatment initiation) is a commendable 
idea., arguably the authors should have considered this as 
a time-updated variable, or started their model at the later 
1-year follow-up time point (as opposed to starting their 
model at the point of completing treatment). Including 
covariates in a Cox regression model that were measured 
after time zero, violates a basic rule of survival analysis (12) 
Another weakness is that the authors do not report the 
predictive performance of their HCC tool in the terms of 
the C-statistic or any other standard measures of model 
performance. This stops us from comparing its performance 
to alternative prediction models available such as the US 
Veteran Affairs HCC models (13) or the Toronto HCC 
Risk Index (14). So as things stand, we have no idea which 
model is the more accurate.
All in all, the study by Pons  et al.  advances our 
understanding into the predictors of liver-related events 
following an HCV cure in patients with compensated 
cirrhosis. The authors have created a visual tool that 
clinicians can use to predict a patient’s 1–3-year risk of 
HCC. But we would suggest that it should be used with 
caution for now, until its performance/accuracy has been 
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